| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Sverre E. Kjeldsen | Q45903512 |
| Luis Miguel Ruilope | Q56550076 | ||
| P2093 | author name string | Tonje A Aksnes | |
| P2860 | cites work | MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party | Q24541570 |
| Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies | Q24658205 | ||
| Arm position during ambulatory blood pressure monitoring: a review of the evidence and clinical guidelines | Q26851169 | ||
| Ambulatory blood pressure monitoring in the diagnosis and management of hypertension | Q26999957 | ||
| Cardiorenal end points in a trial of aliskiren for type 2 diabetes | Q28278569 | ||
| Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: a systematic review and meta-analysis | Q28482437 | ||
| 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8) | Q29617334 | ||
| Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group | Q29617736 | ||
| Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group | Q29619460 | ||
| Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients | Q29619542 | ||
| Usefulness of ambulatory blood pressure monitoring (ABPM) in daily clinical practice: Data from the Spanish ABPM registry | Q30634009 | ||
| Noninvasive 24-h ambulatory blood pressure and cardiovascular disease: a systematic review and meta-analysis | Q30844403 | ||
| Definition of ambulatory blood pressure targets for diagnosis and treatment of hypertension in relation to clinic blood pressure: prospective cohort study | Q33790456 | ||
| Effects of intensive blood-pressure control in type 2 diabetes mellitus | Q34008161 | ||
| The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials | Q34140880 | ||
| Cost-effectiveness of options for the diagnosis of high blood pressure in primary care: a modelling study | Q34210937 | ||
| Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials | Q34276433 | ||
| Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial | Q34327991 | ||
| Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial | Q34346106 | ||
| 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). | Q34351265 | ||
| Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial | Q34366640 | ||
| Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol | Q34522261 | ||
| Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). | Q34539439 | ||
| Targets and self-management for the control of blood pressure in stroke and at risk groups (TASMIN-SR): protocol for a randomised controlled trial. | Q34632829 | ||
| 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension | Q34673532 | ||
| Lowering blood pressure reduces renal events in type 2 diabetes | Q37146445 | ||
| Bottom blood pressure or bottom cardiovascular risk? How far can cardiovascular risk be reduced? | Q37535457 | ||
| Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis | Q37708610 | ||
| Management of high blood pressure in Blacks: an update of the International Society on Hypertension in Blacks consensus statement | Q37797817 | ||
| Home measurement of blood pressure and cardiovascular disease: systematic review and meta-analysis of prospective studies | Q37975418 | ||
| Controversies in blood pressure goal guidelines and masked hypertension | Q38006742 | ||
| Are fixed-dose combination antihypertensives suitable as first-line therapy? | Q38043566 | ||
| A systematic review of patient self-reported barriers of adherence to antihypertensive medications using the world health organization multidimensional adherence model. | Q38064498 | ||
| Blood pressure variability over 24 h: prognostic implications and treatment perspectives. An assessment using the smoothness index with telmisartan-amlodipine monotherapy and combination | Q38168671 | ||
| Effects of prehypertension and hypertension subtype on cardiovascular disease in the Asia-Pacific Region | Q39622914 | ||
| Antihypertensive treatment and blood pressure in diabetic and nondiabetic patients: the lower, the better? | Q39988729 | ||
| Is a systolic blood pressure target <140 mmHg indicated in all hypertensives? Subgroup analyses of findings from the randomized FEVER trial. | Q40333059 | ||
| The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients | Q40494733 | ||
| Target blood pressure for treatment of isolated systolic hypertension in the elderly: valsartan in elderly isolated systolic hypertension study | Q43041888 | ||
| Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke | Q43130723 | ||
| Long-term prognostic value of white coat hypertension: an insight from diagnostic use of both ambulatory and home blood pressure measurements | Q43821611 | ||
| Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes | Q43889672 | ||
| 2013 ambulatory blood pressure monitoring recommendations for the diagnosis of adult hypertension, assessment of cardiovascular and other hypertension-associated risk, and attainment of therapeutic goals | Q44360459 | ||
| Combination of lisinopril and nifedipine GITS increases blood pressure control compared with single drugs in essential hypertensive patients | Q44376981 | ||
| Blood pressure control by the nifedipine GITS-telmisartan combination in patients at high cardiovascular risk: the TALENT study | Q44508851 | ||
| Effects of the combination of low-dose nifedipine GITS 20 mg and losartan 50 mg in patients with mild to moderate hypertension | Q44723496 | ||
| Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial | Q44945181 | ||
| Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension | Q44990922 | ||
| Ambulatory versus clinic blood pressure for the assessment of anti hypertensive efficacy in clinical trials: insights from the Val-Syst Study | Q45142444 | ||
| Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). | Q46165838 | ||
| Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients | Q46217490 | ||
| Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. | Q46426098 | ||
| Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document | Q56970676 | ||
| European Society of Hypertension Position Paper on Ambulatory Blood Pressure Monitoring | Q57085349 | ||
| Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial | Q57085426 | ||
| Angiotensin-Converting Enzyme Inhibitors and Calcium Channel Blockers for Coronary Heart Disease and Stroke Prevention | Q57085525 | ||
| Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial | Q57583292 | ||
| Combination Therapy Versus Monotherapy in Reducing Blood Pressure: Meta-analysis on 11,000 Participants from 42 Trials | Q58133760 | ||
| ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Gu | Q58975447 | ||
| When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal | Q61456541 | ||
| The effect of treatment on mortality in "mild" hypertension: results of the hypertension detection and follow-up program | Q70434950 | ||
| Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators | Q72998299 | ||
| Cost of poor blood pressure control in the UK: 62,000 unnecessary deaths per year | Q73563346 | ||
| Combination antihypertensive drugs: recommendations for use | Q73854021 | ||
| Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials | Q81897757 | ||
| Ambulatory and home blood pressure measurement: complementary rather than competitive methods | Q82503024 | ||
| [2010 Chinese guidelines for the management of hypertension] | Q82528415 | ||
| Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) | Q83112096 | ||
| Blood pressure and risk of cardiovascular diseases in type 2 diabetes: further findings from the Swedish National Diabetes Register (NDR-BP II) | Q84748873 | ||
| Effects of calcium antagonists on the risks of coronary heart disease, cancer and bleeding. Ad Hoc Subcommittee of the Liaison Committee of the World Health Organisation and the International Society of Hypertension | Q93899573 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 4.0 International | Q34179348 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antihypertensive drug | Q575890 |
| ambulatory blood pressure monitoring | Q3090739 | ||
| arterial hypertension | Q41861 | ||
| mechanism of action | Q3271540 | ||
| P304 | page(s) | 31-43 | |
| P577 | publication date | 2014-06-01 | |
| P1433 | published in | Drugs in R & D | Q26842117 |
| P1476 | title | Clinical implications of the 2013 ESH/ESC hypertension guidelines: targets, choice of therapy, and blood pressure monitoring | |
| P478 | volume | 14 |
| Q34172729 | Completion of therapeutic and safety monitoring tests in Lebanese outpatients on chronic medications: a cross-sectional study |
| Q37548017 | Interactions between CYP11B2 Promoter Methylation and Smoking Increase Risk of Essential Hypertension. |
| Q37670943 | New generations of dihydropyridines for treatment of hypertension |
| Q34764232 | Safety and effectiveness of a fixed-dose combination of olmesartan, amlodipine, and hydrochlorothiazide in clinical practice |
| Q49380661 | Synergism of amlodipine and candesartan on blood pressure reduction and organ protection in hypertensive rats |
| Q38363840 | The cost-effectiveness of irbesartan for hypertension |
Search more.